Next Article in Journal
Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: Relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory Cytokines
Previous Article in Journal
Novel Stability-Indicating RP-HPLC Method for the Simultaneous Estimation of Clindamycin Phosphate and Adapalene along with Preservatives in Topical Gel Formulations
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sci. Pharm.
Volume 79
Issue 3
10.3797/scipharm.1104-16
scipharm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Communication

In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1)

by
Eamon P. RAFFERTY
1,
Alastair R. WYLIE
2,
Chris T. ELLIOTT
1,
Olivier P. CHEVALLIER
1,
David J. GRIEVE
3 and
Brian D. GREEN
1,*
1
School of Biological Sciences, Queen’s University Belfast, BT9 5AG, Northern Ireland, United Kingdom
2
Agri-Food and Biosciences Institute, Newforge Lane, BT9 5PX, Belfast, Northern Ireland, United Kingdom
3
School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland, United Kingdom
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2011, 79(3), 615-622; https://doi.org/10.3797/scipharm.1104-16
Submission received: 20 April 2011 / Accepted: 9 June 2011 / Published: 9 June 2011
Versions Notes

Abstract

Glucagon-like peptide-1 (GLP-1) is an intestinal hormone with well-established glucose-lowering activity. The in vitro and in vivo actions of natural putative secretagogues of GLP-1 were investigated. The acute GLP-1 releasing activity of olive leaf extract (OLE), glutamine (GLN), alpha casein (ACAS), beta casein (BCAS) and chlorogenic acid (CGA) were assessed in STC-1 cells and C57BL/6 mice. All compounds except ACAS significantly increased acute in vitro GLP-1 secretion (66-386%; P<0.05–0.001). Oral gavage of OLE and GLN modestly increased plasma GLP-1 concentrations (48% and 41%, respectively), but did not lower glycaemic excursions. OLE and GLN are potent stimulators of GLP-1 secretion both in vitro and in vivo and chronic studies should assess their suitability as nutritional therapies for type 2 diabetes.
Keywords: Diabetes; Glucose; Hormone; Secretion; Olive leaf extract; Glutamine; Casein; Chlorogenic acid Diabetes; Glucose; Hormone; Secretion; Olive leaf extract; Glutamine; Casein; Chlorogenic acid

Share and Cite

MDPI and ACS Style

RAFFERTY, E.P.; WYLIE, A.R.; ELLIOTT, C.T.; CHEVALLIER, O.P.; GRIEVE, D.J.; GREEN, B.D. In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1). Sci. Pharm. 2011, 79, 615-622. https://doi.org/10.3797/scipharm.1104-16

AMA Style

RAFFERTY EP, WYLIE AR, ELLIOTT CT, CHEVALLIER OP, GRIEVE DJ, GREEN BD. In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1). Scientia Pharmaceutica. 2011; 79(3):615-622. https://doi.org/10.3797/scipharm.1104-16

Chicago/Turabian Style

RAFFERTY, Eamon P., Alastair R. WYLIE, Chris T. ELLIOTT, Olivier P. CHEVALLIER, David J. GRIEVE, and Brian D. GREEN. 2011. "In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1)" Scientia Pharmaceutica 79, no. 3: 615-622. https://doi.org/10.3797/scipharm.1104-16

Article Metrics

Back to TopTop